IGF-1 receptor binding aptamer and use thereof
An IGF-1 receptor aptamer addresses the limitations of insulin and IGF-1 therapies by promoting glucose uptake without cell division, providing a safer and more effective diabetes treatment.
Patent Information
- Application Number
- KR1020230094587
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-10-14
- Filing Date
- 2023-07-20
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2043-07-20
AI Technical Summary
Current diabetes treatments using insulin therapy are limited by significant side effects such as weight gain and hypoglycemic shock, while IGF-1 receptor-based treatments face issues like diabetic retinopathy and cancer risks due to excessive cell division and unproven long-term safety.
Development of an IGF-1 receptor aptamer that selectively binds to the IGF-1 receptor, promoting glucose uptake without cell division, thereby addressing the side effects of insulin and IGF-1 therapies.
The IGF-1 receptor aptamer effectively controls blood glucose levels without weight gain or hypoglycemic shock, reducing the risk of diabetic retinopathy and cancer, offering a safer alternative for diabetes management.
Smart Images

Figure 112023080149393-PAT00007_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to an IGF-1 receptor-binding aptamer and its uses. Background Technology
[0002] Diabetes is a metabolic disease characterized by persistently high blood sugar levels; if it worsens severely, it can lead to death due to complications such as cardiovascular disease, stroke, and chronic kidney failure.
[0003] Due to the Westernization of dietary habits, the diabetes population in Korea has been steadily increasing. Currently, one in seven adults aged 30 or older (14.4%) is diagnosed with diabetes, and the demand for the development of diabetes treatments is expected to continue rising. In particular, injectable insulin preparations hold a high market share of 37% in the diabetes treatment market.
[0004] Insulin therapy involves supplying the insulin necessary for diabetic patients from an external source. It is an essential treatment that serves as a last resort for both patients with Type 1 diabetes, who have problems with insulin production, and patients with Type 2 diabetes, which develops due to insulin resistance but involves the gradual loss of beta-cell function.
[0005] Insulin is an anabolic hormone that activates the synthesis and storage of triglycerides in the liver and adipose tissue. Consequently, insulin administration significantly increases the patient's body weight, which adversely affects their ability to control blood sugar and increases cardiovascular complications. Furthermore, due to the very narrow therapeutic index range of insulin, even a slight overdose can easily cause hypoglycemic shock. Hypoglycemia impairs brain function, leading to mental abnormalities, and in severe cases, can result in coma or death. Despite its importance, the use of insulin therapy is sometimes restricted due to these two major side effects.
[0006] The aforementioned side effects are caused by the inherent characteristics of insulin receptors and are difficult to resolve fundamentally; consequently, there is currently no clear solution to address the unmet needs regarding the side effects of insulin preparations.
[0007] However, blood glucose regulation via the IGF-1 receptor has been proposed as one of the various alternatives to address this issue. The IGF-1 receptor and the insulin receptor originate from the same progenitor gene and possess high homology in protein sequence (~60% homology) and structure. In terms of physiological function, both receptors simultaneously regulate metabolism as well as cell growth and differentiation. While insulin exhibits stronger activity in glucose and lipid metabolism, IGF-1, conversely, shows stronger activity than insulin in cell division, growth, and differentiation.
[0008] Blood glucose control via IGF-1 receptors offers several advantages over insulin receptors. Since the potency and efficacy of increased glucose uptake via IGF-1 receptors are lower than those of insulin receptors, the administration of IGF-1 rarely causes hypoglycemic shock associated with insulin administration. Furthermore, because IGF-1 receptors are expressed only in muscle tissue and are absent in the liver and adipose tissue, IGF-1 administration selectively increases glucose uptake by muscles without affecting fat synthesis or storage. Consequently, the administration of IGF-1 does not lead to body weight gain.
[0009] In particular, in clinical trials in which IGF-1 was administered to patients with type 1 and type 2 diabetes, significant reductions in blood glucose and blood insulin levels comparable to those of insulin were observed. The blood glucose regulating ability of IGF-1 observed over a short period was sufficient to replace insulin, and side effects similar to those of insulin therapy were rarely observed.
[0010] However, clinical trials attempting to utilize IGF-1 as a diabetes treatment ultimately failed. This is due to IGF-1's excessive promotion of cell division. As a powerful growth factor, IGF-1 significantly accelerates cell division, growth, and differentiation. In clinical trials of IGF-1, cases of worsening diabetic retinopathy were observed. This is presumed to be caused by the abnormal proliferation of retinal blood vessels following IGF-1 administration. Furthermore, the safety regarding an increased incidence of cancer with long-term administration of IGF-1 has not been established. IGF-1 receptors are known to play a significant role in the development of cancers such as breast, lung, and ovarian cancer.
[0011] Accordingly, the inventors developed an IGF-1 receptor aptamer as a biased agonist, which is a ligand that selectively activates only specific functions or signaling pathways of the IGF-1 receptor, and confirmed that the aptamer selectively activates metabolic functions (glucose absorption) without promoting cell division. Based on this, they determined that the IGF-1 receptor aptamer could resolve the side effects of IGF-1 and safety issues regarding long-term administration that had been observed in conventional clinical trials, and thus completed the present invention. The problem to be solved
[0012] One objective of the present invention is to provide an IGF-1 receptor aptamer that specifically binds to the IGF-1 receptor and promotes the phosphorylation of the IGF-1 receptor.
[0013] Another objective of the present invention is to provide an IGF-1 receptor agonist comprising an IGF-1 receptor aptamer.
[0014] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of metabolic diseases or cancer containing an IGF-1 receptor aptamer as an active ingredient.
[0015] Another objective of the present invention is to provide a composition for diagnosing diabetes or diabetic complications containing an IGF-1 receptor aptamer as an active ingredient. means of solving the problem
[0016] To achieve the above objective, the present invention provides an IGF-1 receptor aptamer that specifically binds to the IGF-1 receptor and promotes the phosphorylation of the IGF-1 receptor.
[0017] More specifically, an IGF-1 receptor aptamer that specifically binds to an IGF-1 receptor comprising SEQ ID NO. 1 or SEQ ID NO. 2 is provided.
[0018] An "aptamer" is a single-stranded oligonucleotide of 15 to 40 strands that forms a specific three-dimensional structure, has a stem loop structure, and has the property of specifically binding to a specific molecule. Aptamers are compounds that are easy to chemically synthesize, easy to chemically modify, are heat-stable, and have very high specificity for a target.
[0019] Aptamer sequences can be discovered using a method called SELEX (selective evolution of ligands by exponential enrichment), and hundreds of aptamer sequences have already been disclosed. Aptamers are often compared to antibodies in that they bind specifically to targets, but they do not elicit an immune response. Many aptamers capable of binding to a wide range of target molecules, from small organic molecules and peptides to membrane proteins, have continued to be discovered. Aptamers are frequently compared to monoclonal antibodies due to their ability to bind to target molecules with inherently high affinity (usually at the pM level) and specificity; specifically referred to as 'chemical antibodies,' they also hold significant potential as alternative antibodies. Aptamers possess much higher stability compared to antibodies. While protein or antibody drugs cannot be stored or transported at room temperature, aptamers can, and they can even maintain their function after sterilization.
[0020] In this specification, an IGF-1 receptor aptamer refers to an aptamer capable of binding to an IGF-1 receptor with a specific affinity. The IGF-1 receptor may be derived from a human IGF-1 receptor protein, but is not limited thereto.
[0021] The above aptamer is characterized by specifically binding to the IGF-1 receptor and may include a modified base in which the 5th position of the nucleotide base included in the aptamer is substituted with a hydrophobic functional group.
[0022] Unless otherwise specified, the bases used in the aptamers of the present invention other than the modified bases mentioned above are selected from the group consisting of A, G, C, T, and their deoxy forms, and any modifications thereof are described in detail.
[0023] To increase the binding strength and specificity of the above aptamer, the 5th position of the nucleotide base included in the aptamer may be substituted with a hydrophobic functional group. For example, the variable region may contain eight or nine deoxyribose uracil modified by substituting the 5th position of the thymine base in the variable region with a hydrophobic functional group, such as 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine (NapdU) or 5-(N-benzylcarboxyamide)-2'-deoxyuridine. The hydrophobic functional group may include a naphthyl group, a benzyl group, a pyrrolbenzyl group, an isobutyl group, or a tryptophan group, and more preferably, the hydrophobic functional group is a naphthyl group or a benzyl group. The deoxyribose uracil modified by substituting with a naphthyl group is shown in Chemical Formula 1 below, and the deoxyribose uracil modified by substituting with a benzyl group is shown in Chemical Formula 2 below.
[0024] [Chemical Formula 1]
[0025] .
[0026] [Chemical Formula 2]
[0027] .
[0028] Preferably, the aptamer may include SEQ ID NO. 1 or 2. Preferably, the aptamer may essentially include SEQ ID NO. 1 or 2 and additionally include consecutive nucleotides on both sides. FIG. 1 shows aptamers having the sequences of SEQ ID NO. 1 (IGF1R-038) and SEQ ID NO. 2 (IGF1R-062) according to the present invention.
[0029] Sequence number designation Sequence (5'→3') 1 IGF1R-038' CGCGAAGGCCA N ACCGGC N CA N GCA NNNN A N CGAGCG 2 IGF1R-062' CGCGAAGGCCA N ACCGGC N CA NN GCA NNNN A N CGAGCG
[0030] N : 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine or 5-(N-benzyl)carboxamide]-2'-deoxyuridine
[0031] In the above chemical formula 1, N may be 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine or 5-(N-benzyl)carboxamide]-2'-deoxyuridine. That is, N is a modified base and may have either a naphthyl group or a benzyl group as a hydrophobic functional group, as referred to in the above chemical formula 1 or 2.
[0032] Preferably, it is 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine, and may be SEQ ID NO. 3 or 4 below.
[0033] Sequence number designation Sequence (5'→3') 3 IGF1R-038 CGCGAAGGCCA N' ACCGGC N' CA N' GCA N'N'N'N' A N' CGAGCG 4 IGF1R-062 CGCGAAGGCCA N' ACCGGC N' CA N'N' GCA N'N'N'N' A N' CGAGCG
[0034] N' : 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine
[0035] The aforementioned C, A, and G may be modified or unmodified bases, and may be substituted with C3 propyl spacers.
[0036] For example, modified C may include the introduction of a methoxy group (2-O-Me, 2-O-Methoxy-DNA) at the second carbon position of the nucleotide; or a modification in which fluorine (2-F, 2-Fluorine-DNA) is introduced at the second carbon position of the nucleotide.
[0037] Specifically, the modified G may include the introduction of a methoxy group (2-O-Me, 2-O-Methoxy-DNA) at the second carbon position of the nucleotide; or the introduction of fluorine (2-F, 2-Fluorine-DNA) at the second carbon position of the nucleotide.
[0038] Specifically, modified A may include a modification in which a methoxy group (2-O-Me, 2-O-Methoxy-DNA) is introduced at the second carbon position of the nucleotide; or a modification in which fluorine (2-F, 2-Fluorine-DNA) is introduced at the second carbon position of the nucleotide.
[0039] Preferably, the aptamer can form a stem-loop structure composed of internal nucleotides.
[0040] The aptamer according to the present invention essentially comprises the sequences of SEQ ID NOs. 1 and / or 2 mentioned above. More specifically, it may consist of SEQ ID NOs. 1 and 2, essentially constitute the same, or include the same.
[0041] More specifically, the above sequence may include a nucleotide sequence having homology of 70% or more, 80% or more, 85% or more, or 90% or more.
[0042] In addition, the above sequence may be approximately at least 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 consecutive sequences.
[0043] For example, it may be sequence number 5 or 6 below.
[0044] Sequence number designation Sequence (5'→3') 5 IGF1R-038'' TATCGAGCGTCCTGCCTTTGAACGCGAAGGCCA N ACCGGC N CA N GCA NNNN A N CGAGCGACACCGACAGCCACCCAGAAA 6 IGF1R-062'' TATCGAGCGTCCTGCCTTTGAACGCGAAGGCCA N ACCGGC N CA NN GCA NNNN A N CGAGCGACACCGACAGCCACCCAGAAA
[0045] N : 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine or 5-(N-benzyl)carboxamide]-2'-deoxyuridine
[0046] In the above chemical formula 1, N may be 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine or 5-(N-benzyl)carboxamide]-2'-deoxyuridine. That is, N is a modified base and may have either a naphthyl group or a benzyl group as a hydrophobic functional group, as referred to in the above chemical formula 1 or 2.
[0048] As a preferred example, it is 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine, which may be SEQ ID NO. 7 or 8 below.
[0049] Sequence number designation Sequence (5'→3') 7 IGF1R-038''' TATCGAGCGTCCTGCCTTTGAACGCGAAGGCCA N' ACCGGC N' CA N' GCA N'N'N'N' A N' CGAGCGACACCGACAGCCACCCAGAAA 8 IGF1R-062''' TATCGAGCGTCCTGCCTTTGAACGCGAAGGCCA N' ACCGGC N' CA N'N' GCA N'N'N'N' A N' CGAGCGACACCGACAGCCACCCAGAAA
[0050] N' : 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine
[0051] In the present invention, including a sequence may mean including a sequence, may mean essentially composed of these, and may mean composed of these.
[0052] In addition, at any base sequence other than the position of N in SEQ ID NO. 1 and / or SEQ ID NO. 2, at least one base located at the 5' end, 3' end, middle, or both ends may be modified to enhance stability in serum or to regulate renal clearance. The modification may be achieved by binding one or more selected from the group consisting of PEG (polyethylene glycol), biotin, idT (inverted deoxythymidine), LNA (Locked Nucleic Acid), 2'-methoxynucleoside, 2'-aminonucleoside, 2'F-nucleoside, amine linker, thiol linker, and cholesterol to the 5' end, 3' end, middle, or both ends. The 2'-methoxynucleoside, 2'-aminonucleoside, or 2'F-nucleoside confers nuclease resistance by binding to a base contained in the aptamer and providing a modified base.
[0053] Preferably, to ensure nuclease resistance and stability upon administration into the human body, it may further include modified bases. Preferably, these modified bases may be substitutions of 2'-OMe (methoxy) and / or 2'-F (fluorine) for any A, C, T, or G base. That is, they may have at least one modified base substitution of 2'-OMe (methoxy) or 2'-F (fluorine) for the A, C, T, or G bases of SEQ ID NO. 1 and / or SEQ ID NO. 2.
[0055] The inventors performed SELEX using an IGF-1 receptor protein and newly selected aptamers that bind more strongly to the IGF-1 receptor. The two types of aptamers selected in this way are the IGF1R-038 (Sequence No. 3) and IGF1R-062 aptamers (Sequence No. 4) described above.
[0056] The aptamer according to the present invention promotes the phosphorylation of the IGF-1 receptor, specifically by preferentially phosphorylating the 1135th tyrosine (Y1135) in the amino acid sequence of the IGF-1 receptor and subsequently promoting the phosphorylation of the 473rd serine (AKT S473) of the AKT, thereby enabling the absorption of glucose.
[0057] In addition, unlike IGF-1, the aptamer according to the present invention does not promote cell division.
[0058] Unlike insulin administration, IGF-1 rarely causes hypoglycemic shock and does not lead to weight gain. However, as a powerful growth factor that significantly promotes cell division, growth, and differentiation, cases have been observed where it exacerbates diabetic retinopathy, and it is known to play a significant role in the development of cancers such as breast, lung, and ovarian cancer.
[0059] The inventors have confirmed through one embodiment that the aptamer increases glucose uptake by cells to a degree comparable to insulin without promoting cell division, and thus the aptamer according to the present invention can be usefully used for blood sugar control without exhibiting the side effects associated with conventional insulin and IGF-1.
[0061] According to the present invention, two or more aptamers may be linked to exist as a dimer or a multimer.
[0062] The formation of a dimer or multimer is achieved by implementing a dimer or multimer form by combining two or more aptamers through a complementary nucleic acid sequence and / or by implementing a single-strand form by combining two or more aptamers through a spacer sequence.
[0063] "Linker sequence" refers to a chemical moiety that connects two molecules or moiety. The linker sequence of the present invention corresponds to, for example, a nucleic acid linker, and forms a dimer by forming a double bond through base sequences that act complementarily to each other. Additionally, if necessary, two or more linker sequences may be included to form a multimer.
[0064] The linker sequence having the above complementary sequence may, for example, be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, or 60 sequences, preferably 5 to 30, 10 to 30, approximately 15 to 25 base sequences, and more preferably about 20 base sequences.
[0065] The linker sequence may further include modified bases to ensure nuclease resistance and stability upon administration into the human body. Preferably, these modified bases may be substitutions of 2'-OMe (methoxy) and / or 2'-F (fluorine) for any A, C, T, or G base, and may be L-form DNA or LNA (Locked DNA). That is, the base sequence of the linker sequence may have at least one modified base substitution of 2'-OMe (methoxy) or 2'-F (fluorine) for A, C, T, or G bases, and the form of the linker sequence as L-form DNA or LNA (Locked DNA) may be used.
[0066] Additionally, if necessary, a spacer sequence may be further included to provide appropriate space between these linker sequences and the sequences of SEQ ID NO. 1 and / or 2. The sequence for providing space between the linker and the aptamer sequence forming this complementary bond is preferably, for example, a polyT and may be included between the linker and the insulin receptor at levels of approximately 0, 1, 2, 3, 4, 5, or 6.
[0067] The spacer sequence may utilize a poly A fragment, a poly T fragment, a poly G fragment, a poly C fragment, a phosphoramidite fragment, a random oligonucleotide sequence that does not interfere with the aptamer sequence, an ethylene glycol fragment, and a propyl fragment. The lengths of these fragments may vary as known to those skilled in the art. Preferably, there may be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30 poly T fragment sequences.
[0068] The spacer sequence may further include modified bases to ensure nuclease resistance and stability upon administration into the human body. Preferably, these modified bases may be substitutions of 3'-propyl spacer, 2'-OMe (methoxy) and / or 2'-F (fluorine) for any A, C, T, or G base, and may be L-form DNA or LNA (Locked DNA). That is, the base sequence of the linker sequence may have at least one modified base substitution of 2'-OMe (methoxy) or 2'-F (fluorine) for A, C, T, or G bases, and the form of the linker sequence as L-form DNA or LNA (Locked DNA) may be used.
[0070] The present invention provides an IGF-1 receptor agonist comprising the above-described aptamer.
[0071] In the present invention, the term "IGF-1 receptor agonist" refers to a pharmaceutically acceptable agent that selectively binds to the IGF-1 receptor. Typically, an IGF-1 receptor agonist refers to a new class of diabetes treatments developed to effectively control blood glucose. The IGF-1 receptor agonist of the present invention is characterized not only by specifically binding to the IGF-1 receptor but also by the absence of side effects such as diabetic retinopathy and cancer development.
[0073] Therefore, the above-mentioned IGF-1 receptor agonist can be used for the diagnosis or treatment of various insulin-related diseases, particularly metabolic diseases.
[0074] Accordingly, the present invention provides a pharmaceutical composition for the prevention or treatment of metabolic diseases or cancer comprising the above-described aptamer in another form.
[0075] For example, metabolic diseases include diabetes mellitus (T1D and / or T2DM, e.g., prediabetes), idiopathic type 1 diabetes mellitus (T1D (type 1b)), latent autoimmune diabetes mellitus in adults (LADA), early-onset type 2 diabetes mellitus (T2DM (EOD)), atypical diabetes mellitus onset in minors (YOAD), adult-onset diabetes mellitus in minors (MODY), malnutrition-related diabetes mellitus, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, renal diseases (e.g., acute renal injury, tubular dysfunction, pro-inflammatory changes in the proximal tubules), diabetic retinopathy, adipocyte dysfunction, visceral fat accumulation, sleep apnea, obesity (e.g., hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urinary incontinence), eating disorders (e.g., bulimia nervosa, bulimia nervosa), and syndromic obesity, e.g. It may be Prader-Willi syndrome and Bardet-Biedl syndrome), weight gain due to the use of other drugs (e.g., from the use of steroids and antipsychotics), excessive sugar intake, dyslipidemia (including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL cholesterol, and low HDL cholesterol), and non-alcoholic fatty liver disease (NAFLD) (including related diseases, e.g., steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma).
[0076] Specifically, the cancer may be any one selected from the group consisting of Ewing sarcoma, rhabdomyosarcoma, multiple myeloma, lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, pancreatic cancer, rectal cancer, colon cancer, colorectal cancer, cervical cancer, and bile duct cancer.
[0077] In particular, the aptamer of the present invention inhibits the activity (expression) of the IGF-1 receptor (IGF-1R), thereby providing an anticancer effect against cancers with high IGF receptor expression.
[0078] More specifically, it may be a cancer with high expression of IGF receptors. Such cancers with high expression of IGF receptors may be any one selected from the group consisting of Ewing sarcoma, rhabdomyosarcoma, multiple myeloma, lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, pancreatic cancer, rectal cancer, colon cancer, colorectal cancer, cervical cancer, and biliary tract cancer.
[0079] In the present invention, "pharmaceuticalally effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the patient's sexually transmitted disease, age, type and severity of the disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0080] The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. Furthermore, the pharmaceutical composition of the present invention may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects, taking all of the above factors into consideration, and this can be easily determined by a person skilled in the art.
[0081] More preferably, the pharmaceutical composition according to the present invention may be administered alone or in combination with insulin. The pharmaceutical composition according to the present invention can reduce the side effects experienced by patients with severe diabetes by lowering the amount of insulin used through co-administration with or replacement with insulin.
[0082] The term "subject" in the present invention includes animals or humans whose symptoms may be improved by the administration of the pharmaceutical composition according to the present invention. By administering the therapeutic composition according to the present invention to an individual, metabolic diseases or cancer can be effectively prevented and treated.
[0083] The term "administration" in the present invention means introducing a specific substance into a human or animal by any appropriate method, and the route of administration of the therapeutic composition according to the present invention may be oral or parenteral through any general route as long as it can reach the target tissue. Additionally, the therapeutic composition according to the present invention may be administered by any device capable of delivering the active ingredient to target cells.
[0084] The preferred dosage of the pharmaceutical composition according to the present invention varies depending on the patient's condition and weight, the degree of disease, the form of the drug, the route of administration, and the duration, but can be appropriately selected by those skilled in the art.
[0085] The above pharmaceutical composition may be formulated into various forms for oral administration or parenteral administration. For example, it may be any oral formulation such as tablets, pills, hard / soft capsules, liquids, suspensions, emulsifiers, syrups, granules, elixirs, etc. Depending on the conventional composition of each formulation, such oral formulations may include, in addition to the above active ingredient, pharmaceutically acceptable carriers such as diluents such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine, or lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol.
[0086] In addition, when the above oral formulation is a tablet, it may include a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and in some cases, it may include a disintegrant such as starch, agar, alginic acid or its sodium salt, a boiling mixture and / or an absorbent, a coloring agent, a flavoring agent or a sweetener, etc.
[0087] When provided for parenteral use, the formulation may be, for example, a liquid formulation, a gel formulation, a cleansing composition, an insertable tablet, a suppository, a cream, an ointment, a dressing solution, a spray, or other topical agent, a liquid formulation such as a solution, a suspension, or an emulsion, and may include a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized preparation, a suppository, a cream, an ointment, a jelly, a foam, a cleanser, or an insert, preferably a liquid formulation, a gel formulation, a cleansing composition, or an insertable tablet. The formulation may be prepared, for example, by adding a solubilizing agent, an emulsifier, a buffer for pH adjustment, etc., to sterile water. The non-aqueous solvent or suspension solvent may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, or injectable esters such as ethyl oleate.
[0088] If necessary, aptamers may be encapsulated within colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or macroemulsions, for example, within microcapsules prepared by coacervation technology or interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively. Such technologies are known in the relevant art.
[0089] The pharmaceutical composition according to the present invention may be administered in a pharmaceutically effective amount. "Pharmaceuticalally effective amount" means an amount sufficient to prevent or treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The effective dose level may be selected by those skilled in the art according to factors such as the method of formulation, the patient's condition and body weight, the patient's gender, age, severity of the disease, drug form, route and duration of administration, rate of excretion, response responsiveness, etc. As is recognized by those skilled in the art, the effective amount may vary depending on the route of treatment, the use of excipients, and the possibility of co-administration with other agents. However, for a desirable effect, in the case of oral formulations, the composition of the present invention may generally be administered to adults at a dose of 0.0001 to 100 mg / kg per day, preferably 0.001 to 100 mg / kg per day of body weight, but said dose does not limit the scope of the present invention in any way.
[0090] In addition, the above pharmaceutical composition may be formulated into a parenteral administration form, in which case it is administered by parenteral administration methods such as subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. At this time, in order to formulate the above pharmaceutical composition into a parenteral administration form, the active ingredient, namely a derivative of Formula I or a pharmaceutically acceptable salt thereof, is mixed in water with a stabilizer or a buffer to prepare a solution or suspension, and such solution or suspension may be prepared into a unit dosage form in an ampoule or vial.
[0091] In addition, the above pharmaceutical composition may be sterilized or further include auxiliary agents such as preservatives, stabilizers, hydrating agents or emulsification promoters, salts and / or buffers for osmotic pressure regulation, and further include other therapeutically useful substances, and may be formulated according to conventional methods of mixing, granulation, or coating.
[0092] The subjects of administration of the pharmaceutical composition of the present invention may be mammals including humans, preferably rodents or humans.
[0093] Meanwhile, since the aptamer according to the present invention can effectively absorb glucose, the present invention may additionally provide a blood glucose-lowering agent comprising the said aptamer as an active ingredient in another form.
[0094] At this time, more preferably, the blood glucose-lowering agent may be administered via subcutaneous injection to provide an immediate effect.
[0096] The present invention provides a method for the prevention or treatment of metabolic diseases or cancer, comprising the step of administering the above-mentioned aptamer to a subject who requires it.
[0097] The present invention provides a composition comprising the aforementioned aptamer for use in the prevention or treatment of metabolic diseases or cancer.
[0098] The present invention provides a use of the aforementioned aptamer in the manufacture of a drug for the treatment of metabolic diseases or cancer.
[0099] In another aspect, the present invention provides a composition for diagnosing diabetes or diabetes complications containing the above-mentioned aptamer as an active ingredient.
[0100] The diagnostic composition according to the present invention can be used by reacting with a biological sample. Through this reaction, the aptamer according to the present invention binds to the IGF-1 receptor in the biological sample. When the degree of binding of the aptamer according to the present invention is higher than that of a normal sample, it can be diagnosed as diabetes or a complication of diabetes.
[0101] The degree of binding of the aptamer according to the present invention to the above biological sample can be determined using DNA aptamer binding measurement techniques commonly used in the relevant technical field. For example, methods such as labeling the aptamer ends with fluorescent or radioactive materials to measure fluorescence or radioactivity intensity, or imaging and observing, may be used, but are not limited thereto. Effects of the invention
[0102] The aptamer according to the present invention can function as a biased agonist that promotes the phosphorylation of the IGF-1 receptor to increase glucose uptake while selectively inducing only the metabolic function of the IGF-1 receptor. In addition, since it does not promote cell division, it can resolve the induction of diabetic retinopathy or cancer caused by excessive cell division resulting from conventional IGF-1 administration. Brief explanation of the drawing
[0103] Figure 1 shows the sequences of IGF1R-038 and IGF1R-062 aptamers according to the present invention. Figure 2 is the result of confirming whether IGF-1 receptor phosphorylation occurred by IGF1R-038 and IGF1R-062 aptamers according to the present invention. Figure 3 is the result of confirming whether IGF-1 receptor, AKT, and ERK were phosphorylated by the IGF1R-038 aptamer according to the present invention. Figure 4 is the result of confirming the inhibitory effect on the activity of IGF-1 by the IGF1R-038 aptamer according to the present invention. Figure 5 is the result of confirming glucose absorption according to the concentration of IGF1R-038 aptamer according to the present invention. Figure 6 shows the results of confirming the effect on cell growth when MCF-7 cells were treated with IGF-1 and IGF1R-038 according to the present invention, each alone. Specific details for implementing the invention
[0104] Examples are provided to aid in understanding the present invention. The following examples and experimental examples are provided merely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by these examples.
[0106] Preparation of antibodies and reagents
[0107] Human IGF-1 receptor protein was purchased from R&D System (Minneapolie, MN). The aptamers used were synthesized by Aptamer Sciences Co., Ltd. The antibodies used for Western blot are as follows: Anti-phosphor-IGF-1R (Y1135), Anti-IGF-1R, Anti-phosphor-ERK (T202 / Y204), Anti-phosphor-AKT (S473), Anti-phosphor-AKT (T308), and Anti-actin were purchased from Cell Signaling (Beverly, MA). Anti-phosphor-IGF-1R (Y1135 / Y1136) was purchased from Invitrogen (Carlsbad, CA).
[0109] cell culture
[0110] CHO cells, MCF-7 cells, and L6 myoblast cells were purchased from the American Type Culture Collection (Manassas, VA, USA). 293F cells were purchased from Thermo Scientific. MCF-7, 293F, and Rat-1 / hIR were cultured in DMEM (Dulbecco's modified Eagle's medium, Lonza) supplemented with 10% FBS (fetal bovine serum, Gibco), 100 units / mL penicillin, and 100 units / mL streptomycin at 37°C and 5% CO2. L6 myoblast cells were cultured in Alpha MEM (WELGEN) supplemented with 10% bovine serum (Gibco), 100 units / mL penicillin, and 100 units / mL streptomycin at 37°C and 5% CO2.
[0112] Example 1. Discovery of IGF-1 Receptor Aptamers
[0113] Aptamers that bind to the extracellular region of the insulin receptor were discovered using SELEX. SELEX was performed using a single-stranded DNA library (Sequence No. 3) consisting of a 40-mer variable sequence and an immutable sequence with 20-mers on each side.
[0115] 1.1 Synthesis of Modified Nucleic Acid Libraries
[0116] To prepare the single-strand modified DNA library required for SELEX, an antisense library (SEQ No. 3) with biotin bound to the 5' was synthesized. Double-stranded DNA was prepared by reacting the antisense library with a 50 μM reverse primer (SEQ No. 4) for 1 hour at 70°C in 0.5 mM dNTPs (ATP, GTP, CTP, Bz-dU), 0.25 U / µL KOD XL (Invitrogen), and 10X extension buffer (1.2 M Tris-HCl pH 7.8, 100 mM KCl, 60 mM (NH4)2SO4, 70 mM MgSO4, 1% TritonX-100, 1 mg / mL BSA). The single-strand modified DNA library was eluted with 20 mM NaOH and then neutralized with an HCl solution. The prepared DNA library was concentrated using Amicon Ultra-15 (Millipore) and then quantified using a UV spectrophotometer.
[0118] 1.2 Binding to IGF-1 receptors
[0119] 1 nM of the synthesized library was added to a selection buffer (200 mM HEPES, 510 mM NaCl, 25 mM KCl, 25 mM MgCl2) and reacted for 5 minutes at 95°C, 70°C, 48°C, and 37°C, respectively. Then, for negative selection, 10 μl of 10X protein competition buffer (10 μM prothrombin, 10 μM casein, 0.1% (w / v) HSA (human serum albumin, SIGMA)) was mixed, and the mixture was added to Dynabeads® MyOne™ Streptavidin C1 (SA bead) (50% (v / v) slurry, 10 mg / mL Invitrogen) from which the supernatant had been removed, and reacted for 10 minutes at 37°C.
[0120] After the negative selection reaction, only the supernatant was taken and transferred to a new tube, then reacted with Dynabead TALON bound to a His-tag IGF-1 receptor protein at 37°C for 1 hour. The Dynabeads TALON bound to DNA and the IGF-1 receptor was washed 5 times with 100 µl of selection buffer (200 mM HEPES, 510 mM NaCl, 25 mM KCl, 25 mM MgCl2). For the 5th wash, the sample was transferred to a new plate. 85 µl of 2 mM NaOH solution was added to elute the target-binding library, and the solution was neutralized with 20 µl of 8 mM HCl solution.
[0122] 1.3 Amplification
[0123] Library DNA that binds to the target was amplified using QPCR (quantitative PCR, IQ5 multicolor real time PCR detection system, Bio-rad). The reverse primer (SEQ No. 4) and antisense library (SEQ No. 3) used in the library preparation were mixed with 5 μM (5 X QPCR master Mix, Novagen), 0.075 U / µL KOD (Novagen), 1 mM dNTP (Roche Applied Science), 25 mM MgCl2, and 5X SYBRgreen I (Invitrogen) to make a total volume of 125 μL, and a double-stranded library was prepared by performing the process once under conditions of 96°C for 15 seconds, 55°C for 10 seconds, and 68°C for 30 minutes, and repeating the process 30 times under conditions of 96°C for 15 seconds and 72°C for 1 minute.
[0125] 1.4 eDNA Production
[0126] eDNA refers to enzymatic DNA, meaning an aptamer produced using a DNA template and polymerase. The DNA library produced through the above QPCR was immobilized by mixing it in 25 µl of Myone SA beads (Invitrogen) at room temperature for 10 minutes. The amount of DNA mixed was set to 60 µl as the QPCR product. 20 mM NaOH solution was added to convert it into single-stranded DNA. Then, DNA containing modified nucleic acids was synthesized using the same method as the library preparation in Example 1.1 and used for the next round. A total of 8 SELEX rounds were performed. To ensure more selective binding, DNA aptamers were selected by diluting the DNA and protein (IntegrinαVβ3) complex in 10 mM DxSO4(sigma) solution at 1 / 200 and 1 / 400, respectively, from rounds 4 to 6 and from rounds 7 to 8.
[0128] 1.5 Aptamer Sequencing Analysis
[0129] After 8 rounds of SELEX, the results were amplified into double-stranded DNA using the QPCR method and purified using the QIAquick PCR Purification Kit (QIAGEN). The DNA sequences were analyzed using an Illumina NextSeq500 in a 150-paired-end-read format.
[0131] Experimental Example 1. Evaluation of Phosphorylation of IGF-1 Receptor Aptamer
[0132] 1.1 Western Blot
[0133] Before treatment with aptamers, cells were treated in FBS-free DMEM for 3 hours to induce serum deprivation. All aptamers were heated at 95°C for 5 minutes and then slowly cooled to room temperature to ensure proper secondary structure formation. The aptamers were treated to cells for 1 hour in Krebs-Ringer HEPES buffer [25 mM HEPES (pH 7.4), 120 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.3 mM CaCl2, and 1.3 mM KH2PO4].
[0134] After aptamer treatment, the cells were lysed in lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 10 mM β-glycerophosphate, 2 mM Na3VO4, 1 mM PMSF, 10% glycerol, 1% Triton-X, and protease inhibitor cocktails]. The cell lysates were centrifuged at 14,000 rpm at 95°C for 15 minutes to separate the proteins.
[0135] The prepared cell lysates were electrophoresed on 6%–16% SDS-PAGE and transferred to a nitrocellulose membrane. After incubating the membrane with the primary antibody at 4°C for 12 hours, the secondary antibody conjugated with IRDye800CW (LI-COR) was incubated at room temperature for 1 hour. The presence and phosphorylation levels of proteins were measured using an infrared fluorescence system (Odyssey, LI-COR).
[0137] 1.2 IGF-1 Receptor Phosphorylation
[0138] In order to determine the effect of the IGF1R-038 aptamer and IGF1R-062 aptamer of Example 1 on the phosphorylation of the IGF-1 receptor, the degree of phosphorylation of the IGF-1 receptor was observed using the Western blotting method described above when treated with IGF-1, IGF1R-038 aptamer and IGF1R-062 aptamer.
[0139] As shown in Figure 2, phosphorylation at Y1135 / Y1136 in the IGF-1 receptor kinase region was found to be increased in both the IGF1R-038 and IGF1R-062 aptamer treatment groups.
[0140] As can be seen from the results of this experiment, although IGF1R-062 aptamer has one more base than IGF1R-038 aptamer, no difference in activity was observed between the two aptamers, so it is judged that the two aptamers will have similar functions. Therefore, additional experiments were conducted below, specifically on IGF1R-038 aptamer.
[0142] 1.3 Phosphorylation of Signaling Proteins
[0143] The effect of Y1135 phosphorylation by the IGF1R-038 aptamer of Example 1 on IGF-1 signaling was compared with IGF-1.
[0144] As shown in Fig. 3, the IGF1R-038 aptamer activated signaling comparable to that of IGF-1. In 293F cells treated with IGF-1 (10 nM), the phosphorylation of proteins such as the IGF-1 receptor, AKT, and ERK increased rapidly for 5 minutes and gradually decreased over time. In contrast to IGF-1, the IGF1R-038 aptamer (250 nM) slowly increased the phosphorylation of AKT (S473) over 1 hour, and the phosphorylation persisted for 1 hour. Additionally, the IGF1R-038 aptamer (250 nM) had no effect on the phosphorylation of ERK. Thus, the IGF1R-038 aptamer activates the signaling of the IGF-1 receptor, but it has characteristics distinctly different from the signaling induced by IGF-1.
[0146] Experimental Example 2. Evaluation of IGF-1 activity inhibition by IGF-1 receptor aptamers
[0147] Before treatment with aptamers, cells were treated in FBS-free DMEM for 3 hours to induce serum deprivation. All aptamers were heated at 95°C for 5 minutes and then slowly cooled to room temperature to ensure proper secondary structure formation. 400 nM of IGF1R-038 aptamer was treated with IGF-1 for 10 minutes in Krebs-Ringer HEPES buffer [25 mM HEPES (pH 7.4), 120 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.3 mM CaCl2, and 1.3 mM KH2PO4].
[0148] After aptamer treatment, the cells were lysed in lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 10 mM β-glycerophosphate, 2 mM Na3VO4, 1 mM PMSF, 10% glycerol, 1% Triton-X, and protease inhibitor cocktails]. The cell lysates were centrifuged at 14,000 rpm at 95°C for 15 minutes to separate the proteins.
[0149] The prepared cell lysates were electrophoresed on 6%–16% SDS-PAGE and transferred to a nitrocellulose membrane. After incubating the membrane with the primary antibody at 4°C for 12 hours, the secondary antibody conjugated with IRDye800CW (LI-COR) was incubated at room temperature for 1 hour. The presence and phosphorylation levels of proteins were measured using an infrared fluorescence system (Odyssey, LI-COR).
[0150] As shown in Figure 4, it was confirmed that when IGF1R-038 aptamer was mixed with IGF-1 and treated, it inhibited the effect of IGF-1. This is considered to be the result of IGF1R-038 aptamer competitively binding to IGF-1. These results indicate that IGF1R-038 aptamer acted as a biased inhibitor by inhibiting the activity of IGF-1 while maintaining its own aptamer effect.
[0152] Experimental Example 3. Evaluation of glucose uptake by IGF-1 receptor aptamers
[0153] As the IGF1R-038 aptamer increased the phosphorylation of AKT (S473) through Experimental Example 2 above, we intended to confirm the activity of the IGF1R-038 aptamer on glucose uptake in L6 myocells.
[0154] To this end, L6 myocells were treated with FBS-free DMEM for 1 hour to induce serum deprivation, followed by treatment with Krebs-Ringer HEPES buffer for 1 hour. After treatment with IGF-1 or aptamers at various concentrations (IGF-1: 0.73 nM, 3.12 nM, 12.5 nM, 50 nM, 200 nM; IGF1R-038: 25 nM, 50 nM, 100 nM, 200 nM), 2-deoxy[14C]glucose (0.1 μCi / ml) was added for 10 minutes. The cells were washed three times with PBS containing 20 mM glucose and lysed with a solution containing 0.5 N NaOH and 1% SDS. The amount of glucose (2-Deoxy-D-glucose) absorbed into the cell was observed using a liquid scintillation counter.
[0155] As shown in Figure 5, the IGF1R-038 aptamer exhibited a degree of glucose absorption comparable to that of the insulin and IGF-1 administration groups. In particular, it was confirmed that the IGF1R-038 aptamer treatment group at 100 nM or higher showed a higher level of glucose absorption compared to the insulin treatment group at 200 nM, so it was determined that the IGF1R-038 aptamer is suitable for use in lowering blood glucose.
[0157] Experimental Example 4. Whether cancer cell growth is induced
[0158] The effects of IGF1R-038 aptamers on cell division were investigated using the MCF-7 cancer cell line, which is widely used to test the ability of IGF-1 receptors to induce cell division.
[0159] To this end, MCF-7 cells were seeded at a density of 10,000 per well in a 24-well plate and cultured for 24 hours, followed by an additional 24 hours of culture in 0.5% FBS DMEM for serum deprivation. The cells were treated with IGF-1 and IGF1R-038 alone for 72 hours, respectively, and the medium was replaced every 24 hours. After treatment, the cells were fixed in PBS containing 4% paraformaldehyde at room temperature for 30 minutes. Subsequently, the DNA of the cells was stained with PBS containing 1 μM SYTO60 fluorescent dye, and the cell volume was quantified by measuring fluorescence using a LI-COR Odyssey scanner.
[0160] As shown in Figure 6, when MCF-7 cells were treated with IGF-1, cell division increased 1.85-fold, whereas when treated with IGF1R-038, cell growth was inhibited. This indicates that the signaling of IGF1R-038 does not affect the induction of cell division by the IGF-1 receptor. In other words, it was confirmed that treatment with the IGF1R-038 aptamer can demonstrate therapeutic efficacy without side effects or issues regarding cell division. Furthermore, it was confirmed that it has potential to be utilized as a cancer treatment by inhibiting cancer cell growth.
Claims
Claim 1 An IGF-1 receptor aptamer composed of SEQ ID NO. 1 that specifically binds to the IGF-1 receptor. Claim 2 In claim 1, the aptamer is an IGF-1 receptor aptamer that phosphorylates Y1135 or AKT S473 of the IGF-1 receptor. Claim 3 delete Claim 4 In claim 1, the N group of SEQ ID NO. 1 is an IGF-1 receptor aptamer that specifically binds to an IGF-1 receptor, where the N group is 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine. Claim 5 delete Claim 6 delete Claim 7 In claim 1, the IGF-1 receptor aptamer is one that exists as a dimer or a multimer. Claim 8 An IGF-1 receptor agonist comprising an aptamer selected from the group consisting of claims 1, 2, 4 and 7. Claim 9 A pharmaceutical composition for the prevention or treatment of any one metabolic disease selected from the group consisting of claims 1, 2, 4 and 7, comprising an aptamer selected from the group consisting of claims 1, 2, 4 and 7. Claim 10 delete Claim 11 A pharmaceutical composition for the prevention or treatment of any one cancer selected from the group consisting of Ewing sarcoma, rhabdomyosarcoma, multiple myeloma, lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, pancreatic cancer, rectal cancer, colon cancer, colorectal cancer, cervical cancer, and biliary tract cancer, comprising an aptamer selected from the group consisting of any one of claims 1, 2, 4, and 7. Claim 12 delete
Citation Information
Patent Citations
Aptamer against Insulin Receptor and Pharmaceutical Composition Containing the Same
KR1020170013178A
